(Reuters) - Pfizer Inc and its partner BioNTech said on Thursday that the EU health regulator has recommended authorising the use of their bivalent COVID-19 shot as a booster in children 5 through 11 years of age.
(Reuters) -Pfizer Inc and its partner BioNTech said on Thursday the EU health regulator has recommended authorising the use of their bivalent COVID-19 shot as a booster in children aged 5 through 11.
The Omicron-tailored vaccine is already authorised by the European Commission for individuals aged 12 years and above.
The updated bivalent booster shot targets the original coronavirus strain as well as the BA.4 and BA.5 sub-variants of Omicron.
In October, European Medical Agency backed authorization of Moderna Inc’s COVID-19 tailored booster shots for 12 and above to further vaccination campaigns in the region.
(Reporting by Bhanvi Satija and Khushi Mandowara in Bengaluru; Editing by Shounak Dasgupta amd Shinjini Ganguli)
Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV. Learn more about Thomson Reuters products: